To ensure the health and safety of persons taking antiretroviral medication as preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection, Centers for Disease Control and Prevention guidelines recommend initial and follow-up laboratory testing. We assessed the rates of recommended testing, using a commercial insurance claims database. Before taking PrEP, 45% of users were tested for HIV, 55% for syphilis, 43% for chlamydia/gonorrhea, and 38% for hepatitis B, and 31% had their creatinine level measured. By 6 months after PrEP initiation, 38% were tested for HIV, 49% for syphilis, and 39% for chlamydia/gonorrhea, and 37% had their creatinine level measured. Although laboratory testing was less frequent than recommended, testing rates increased over the study period.
Keywords. HIV; PrEP; preexposure prophylaxis; laboratory monitoring; guideline adherence; United States HIV preexposure prophylaxis (PrEP) is a biomedical prevention strategy that has been found to be highly effective in preventing acquisition of human immunodeficiency virus (HIV) infection [1] [2] [3] . Persons at substantial risk of HIV acquisition can take a single daily pill of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for PrEP. Before the Centers for Disease Control and Prevention (CDC) published comprehensive clinical practice guidelines in 2014 for the use of PrEP [4] , it issued 3 interim guidelines, in 2011, 2012, and 2013, with recommendations for different risk populations [5] [6] [7] . All of these guidelines recommend that TDF/FTC for PrEP should only be prescribed for persons with a negative HIV test result, normal renal function, and known hepatitis B status; syphilis, gonorrhea, and chlamydia testing is also recommended at PrEP initiation. Follow-up healthcare visits are recommended at least every 3 months for assessment of ongoing risk of HIV acquisition, PrEP adherence counseling, and laboratory testing. The CDC recommends that testing be performed for HIV every 3 months, that renal function should be analyzed 3 months after PrEP initiation and then every 6 months, and that sexually transmitted infection (STI) testing be performed every 3-6 months.
Frequent HIV testing of PrEP users can detect infection early, allowing for immediate treatment that preserves immune function and prevents HIV transmission [8] . Because TDF/FTC is inadequate treatment for HIV infection, becoming infected while taking PrEP might result in antiretroviral drug resistance, making detection of HIV infection important. Both decreased renal function and active hepatitis B virus (HBV) infection present potential safety issues for the use of PrEP, and patients with these conditions require close monitoring. A serum creatinine test can be used to evaluate renal function, and PrEP users with active HBV infection require monitoring of their liver function, as hepatic flare is possible when discontinuing PrEP [9] .
Despite the increase in use of PrEP in recent years [10] , studies of healthcare provider adherence to CDC guidelines for the use of PrEP are limited. The goal of this study is to assess the rate of recommended laboratory testing before initiating and during PrEP.
METHODS
We conducted a retrospective cohort study, using data from Truven Health MarketScan Commercial Claims and Encounter databases. The databases contained medical and prescription claims information of persons who had commercial health insurance from >100 health plans and large companies in the United States.
Using a previously developed algorithm [10] , we identified a cohort of persons who filled their first TDF/FTC prescription for PrEP between 1 January 2011 and 31 December 2015. The date of the first prescription fill claim defined the person's index date. We restricted the study cohort to persons who were aged ≥18 years and continuously enrolled in their health plan for ≥6 months. All PrEP users were followed prospectively after the index date until the earliest of the following end points: (1) occurrence of HIV infection, indicated by an HIV infection diagnosis or initiation of treatment with a non-TDF/FTC antiretroviral drug; (2) disenrollment from the health plan; or (3) 31 December 2015, the end of the study period.
Measures
We assessed performance of an initial test on or ≤3 months before the date of the first PrEP prescription, including tests for HIV infection, HBV infection, renal function (by determining the serum creatinine level), and STIs, including syphilis, chlamydia, and gonorrhea. Because chlamydia and gonorrhea screening are typically performed using test kits that combine the 2 tests, we reported tests for chlamydia and gonorrhea as 1 bundled testing event.
We also assessed performance of laboratory monitoring after PrEP initiation, including testing for HIV infection and other STIs, hepatitis B, and creatinine clearance. To exclude shortterm users who did not continue PrEP after the initial prescription or who did not visit a healthcare provider for follow-up care, we included in our cohort only those who had at least 3 months of follow-up and a >90-day supply of TDF/FTC.
Statistical Analysis
We estimated demographic characteristics of the study sample and calculated the percentage of PrEP users who underwent baseline testing. The Cochran-Armitage trend test was used to evaluate whether baseline testing varied by index year. We used Kaplan-Meier time-to-event methods to estimate the time of first follow-up laboratory testing and cumulative percentage of the sample tested at various time points. Separate probability function curves were created by index year and tested for homogeneity, using the log-rank test.
RESULTS

Study Sample
A total of 5257 PrEP users met our study selection criteria (Supplementary Figure 1) . In our PrEP cohort, 62.5% were aged 25-44 years, nearly 98% were male and resided in urban areas, and 33% resided in the western region. The cohort was followed for a median duration of 190 days (interquartile range, 90-360 days), and approximately 70% of PrEP users in the sample were observed until 31 December 2015 (Supplementary Table 1 ).
Performance of Baseline Testing
On or ≤3 months before the date of PrEP initiation, 44.9% of the PrEP users were tested for HIV infection, 30.6% had their serum creatinine level measured, 38.3% were tested for HBV infection, 54.7% were tested for syphilis, and 43.3% were tested for chlamydia/gonorrhea. When stratified by year of PrEP initiation, all laboratory testing at PrEP initiation increased significantly from 2011 to 2015, with the exception of HIV testing. The rate of HIV testing at PrEP initiation increased between 2011 and 2013 and then decreased from 55.7% in 2013 to 38.8% by 2015 (Table 1) .
Performance of Follow-up Testing
Among the 3498 persons who were prescribed PrEP for ≥3 months, recommended assessment of renal function 3 months after PrEP initiation was performed for 22.0% of PrEP users, and by 9 months 44.1% underwent serum creatinine testing. We did not observe a significant trend in the rate of creatinine testing at any follow-up time point, by index year. By 6 months after PrEP initiation, 48.8% of the cohort had a test for syphilis performed, and 39.4% underwent testing for chlamydia/gonorrhea; by 12 months, 65.8% were tested for syphilis, and 55.1% were tested for chlamydia/gonorrhea. Rates of follow-up testing for STIs generally increased over the study years (P < 0.001, by the log-rank test; Table 2 and Supplementary Figure 2) .
A follow-up HIV test was performed for 43.8% of the cohort, and the percentage tested increased from 23.9% by 3 months after PrEP initiation to 47.9% by 12 months. All follow-up laboratory testing rates generally improved from 2011 to 2015, and the HIV testing rate increased between 2011 and 2014 and then decreased between 2014 and 2015 (Table 2 and Supplementary  Figure 3) . 
DISCUSSION
We analyzed a large health services claims database to monitor the quality of care received by commercially insured PrEP users during 2011-2015. We found that laboratory monitoring of PrEP users in accordance with CDC guidelines was suboptimal and that interventions are needed to improve testing rates both at PrEP initiation and during follow-up care. Before PrEP initiation, many PrEP users were not tested for HIV infection and other STIs, HBV infection, or creatinine clearance. The rates of testing at PrEP initiation increased over time, likely because of increased healthcare provider knowledge of CDC recommendations for PrEP [11] . We found that PrEP users were more likely to be tested for STIs at PrEP initiation than for hepatitis B or renal function, probably because a recent STI might have served as a risk indicator for PrEP eligibility [4] . It is also possible that persons underwent hepatitis B testing before the study period or had been vaccinated for hepatitis B and so were not tested at the time of PrEP initiation. Although we observed an increasing time trend in cumulative rates for all recommended follow-up laboratory tests for PrEP users, these rates remained consistently low at 3 months and 6 months, suggesting that these monitoring tests were not performed during the recommended time frame. It is concerning that HIV testing rates before PrEP initiation were 45% overall, despite our permissive criterion of including tests performed within 3 months before PrEP initiation. It is possible that we underestimated HIV testing rates, because a portion of HIV testing was conducted in publically funded healthcare venues, such as STD clinics, did not have the capacity to bill for health services and so would not be captured in the health services claims database.
The decrease in the rate of HIV testing from 2014 to 2015 might indicate an increased use of point-of-care HIV tests. In December 2014, the Food and Drug Administration granted a Clinical Laboratory Improvement Amendments (CLIA) waiver for the Alere Determine HIV-1/2 Ag/Ab Combo test that is a fourth-generation, rapid point-of-care test that can be performed using a whole blood specimen obtained by finger stick. While a point-of-care test can be performed in a laboratory and billed to a health plan, the CLIA waiver made it available for use in physician offices, clinics, and other healthcare venues. Its use in one of these settings would likely not be billed to the PrEP user's health plan. The CDC recommends that HIV testing be performed using the most sensitive HIV tests, to allow detection of acute HIV infection [4] . Among persons who used PrEP, emergence of HIV resistance was observed in those with undiagnosed acute infection [1] . When initiating PrEP and conducting follow-up testing of PrEP users, healthcare providers might consider using a laboratory-based fourth-generation test as recommended [12] . PrEP should not be initiated in persons with impaired renal function [4] . While renal impairment due to TDF/FTC was rare in clinical trials and resolved after discontinuing PrEP [13] , it is important to monitor renal function of PrEP users to ensure its safe use. In our study, rates of serum creatinine testing were low both at PrEP initiation and during follow-up care, and they did not significantly increase over the study period. We anticipate increases in these rates in the future as healthcare providers' knowledge of and experience with PrEP increases. Many resources are available for physicians to guide management of PrEP, including the CDC-sponsored PrEPline (available at: http://nccc.ucsf.edu/clinician-consultation/preppre-exposure-prophylaxis) or by calling 1-855-448-7737 (or 1-855-HIV-PrEP).
STI testing is important for diagnosis and treatment of syphilis, gonorrhea, and chlamydia infections, which are often asymptomatic. These infections serve as objective biomarkers of sexual risk behavior such as condomless sex and can identify PrEP users who might benefit from risk reduction counseling. The lesions and inflammation that these STIs can cause also might facilitate HIV acquisition in PrEP users with suboptimal adherence. Diagnosing and treating STIs also helps to decrease their prevalence in the community. STI screening should be conducted at PrEP initiation and at least every 3-6 months while using PrEP. Screening for chlamydia and gonorrhea at all anatomic sites of exposure can detect rectal or pharyngeal infection that might otherwise be missed with genital screening alone [14] . Sensitive nucleic acid amplification tests can be used performed on urine specimens and on swab specimens from the vagina, rectum, or pharynx [14] .
There were limitations to our study. The algorithm to identify PrEP users might overestimate or underestimate the number of PrEP users. However, a similar algorithm was validated with a medical record review and was found to have high sensitivity and specificity [15] . Laboratory testing data would not be included in the claims database if the services were not billed to a health plan. We could not assess reasons for the lack of follow-up tests: it may be that either the test was not ordered by the providers or that patients did not follow through with testing. Finally, our findings can only be generalized to persons with commercial health insurance.
In summary, our analysis of a large claims database revealed that a cohort of PrEP users were tested for HIV infections, other STIs, and creatinine clearance less frequently than recommended both before PrEP initiation and while using PrEP. It is important that PrEP users be monitored as recommended in the guidelines, to ensure their health and safety while using TDF/FTC. Health clinic policies and operating procedures can help to ensure that recommended tests are performed during follow-up visits at the appropriate intervals. Our analysis provides a feasible method to evaluate the quality of PrEP care that can be used for monitoring in future years.
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